Kidney Cancer Clinical Trial

Clinical Trial Finder Kidney Cancer Trials

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

See Locations Near You

Summary

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Advanced Renal Cell Carcinoma
Must have at least 1 lesion with measurable disease
Life expectancy of at least 3 months
Karnofsky Performance Status (KPS) must be =>70%

Exclusion Criteria:

Patients/subjects with suspected or known central nervous system metastases unless adequately treated
Patients/subjects with autoimmune disease
Patients/subjects who need daily oxygen therapy

Other protocol defined inclusion/exclusion criteria apply

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

182

Study ID:

NCT02996110

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 31 Locations for this study

See Locations Near You

Local Institution - 0037
New Haven Connecticut, 06520, United States
Local Institution
Tampa Florida, 33612, United States
Local Institution - 0031
Augusta Georgia, 30912, United States
Local Institution - 0006
Chicago Illinois, 60612, United States
Local Institution - 0007
Baltimore Maryland, 21287, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Massachusetts General Hospital
Boston Massachusetts, 02215, United States
Local Institution - 0011
Detroit Michigan, 48201, United States
Local Institution - 0008
Saint Louis Missouri, 63110, United States
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
Local Institution - 0005
New York New York, 10065, United States
Local Institution - 0043
Charlotte North Carolina, 28204, United States
Local Institution - 0014
Columbus Ohio, 43210, United States
Oregon Health & Science University
Portland Oregon, 97239, United States
Local Institution - 0002
Allentown Pennsylvania, 18103, United States
Hollings Cancer Center
Charleston South Carolina, 29425, United States
Local Institution - 0025
Nashville Tennessee, 37203, United States
Ut Southwestern Medical Center
Dallas Texas, 75390, United States
Local Institution - 0024
Charlottesville Virginia, 22908, United States
University of Washington - Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
Local Institution - 0032
Westmead New South Wales, 2145, Australia
Monash Medical Centre Clayton
Bentleigh Victoria, 3165, Australia
Local Institution - 0044
Linz Oberösterreich, 4010, Austria
Local Institution - 0038
Hamilton Ontario, L8V 5, Canada
Local Institution - 0029
Oshawa Ontario, L1G 2, Canada
Local Institution - 0035
Toronto Ontario, M5G 1, Canada
Local Institution - 0034
Montreal Quebec, H3T 1, Canada
Local Institution - 0030
Québec Quebec, G1R 2, Canada
Local Institution
Haifa , 31096, Israel
Local Institution
Ramat Gan , 52621, Israel
Local Institution - 0010
Milano , 20133, Italy
Local Institution - 0012
Napoli , 80131, Italy
Load More

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

182

Study ID:

NCT02996110

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider